Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Compounded semaglutide remains available through licensed 503A compounding pharmacies, though regulatory oversight has intensified since 2023. The FDA's focus on unlicensed 503B manufacturers and quality assurance does not eliminate compounded GLP-1 medications from licensed facilities that meet stringent standards.

For patients evaluating treatment options, understanding availability is only one piece of the puzzle. Equally important are biomarker assessments, genetic predispositions in GLP-1 receptor pathways, and how these factors influence individual response—enabling a more precision-focused conversation with your provider.

Regulatory Status of Compounded Semaglutide in 2024

In 2023, the FDA intensified enforcement against unlicensed 503B compounding operations that were manufacturing and distributing semaglutide without proper oversight. This action targeted quality control failures and unverified manufacturing processes, not the legitimacy of compounded medications dispensed by licensed 503A pharmacies.

Licensed 503A compounding pharmacies operate under state pharmacy board oversight and must follow specific criteria: they compound only upon receipt of a valid prescription, maintain sterility and purity standards, and cannot manufacture bulk quantities for sale. Compounded semaglutide from these sources continues to be a legal and accessible option for patients and providers.

Key Differences: Licensed 503A Compounding vs. Unlicensed Operations

The regulatory landscape distinguishes sharply between licensed compounding pharmacies and unlicensed manufacturers. Knowing this difference helps clarify what 'going away' means and protects patient safety. The table below outlines critical distinctions that affect availability and quality assurance.

Attribute Licensed 503A Compounding Pharmacy Unlicensed 503B Operations (Under FDA Enforcement)
Regulatory Oversight State pharmacy board + pharmacy licensing requirements No FDA oversight; no state licensing
Compound-to-Order Model Compounds only after receipt of valid prescription Manufactures bulk supply for wholesale distribution
Quality Standards Follows USP <797> sterility and purity guidelines Variable or absent quality control
Current FDA Status Permitted to operate under compliance framework Subject to FDA warning letters and enforcement action
Patient Access Prescription from licensed healthcare provider required Supplied through unverified retail channels

Biomarker Context: Why Individual Response Varies

Even with compounded semaglutide readily available, not all patients experience the same clinical outcomes. Biomarkers—including baseline insulin resistance, inflammatory markers, and liver function—can provide context for how effectively a given dose may work and what side effects a patient might encounter.

Genetic variants in the GLP-1 receptor (GLP1R), glucose-dependent insulinotropic peptide receptor (GIPR), and other appetite-regulation genes influence how the body responds to semaglutide therapy. These predispositions can inform whether a standard dose, microdose approach, or alternative formulation may align better with your metabolic profile.

How to Make an Informed Decision With Your Provider

Before choosing compounded semaglutide, oral semaglutide, or another GLP-1 option, a collaborative conversation with your provider should address availability, cost, side effect risk, and your individual biomarker and genetic context. Clarifying these factors reduces uncertainty and supports more precise treatment selection.

If you opt for compounded semaglutide, verify that your pharmacy is licensed, state-regulated, and follows USP sterility standards. Request documentation of quality assurance. If genetic predispositions or biomarker results inform your choice, bring those findings to your appointment so your provider can calibrate dosing and monitoring accordingly.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP1R, GIPR, FTO, and MC4R genes to reveal genetic predispositions in peptide signaling pathways. These insights may help provide context for how your body is likely to respond to semaglutide therapy—though genetic testing predicts predispositions, not exact medication outcomes.

The genetic test results should be interpreted with a qualified healthcare provider and used as one component of a broader clinical assessment. Combined with biomarkers such as fasting glucose, HbA1c, triglycerides, and liver function, genetic data can support a more personalized conversation about whether compounded semaglutide or alternative formulations align with your metabolic profile.

For patients concerned about compounded semaglutide availability, understanding your own genetic predispositions and biomarker status empowers you to discuss alternatives—including oral semaglutide, compounded tirzepatide, or microdose protocols—with evidence-informed confidence. This shifts the focus from 'Is it available?' to 'What's the best choice for me?'

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves